The Unfair Advantage: Why Smart Biotechs Run Trials in Australia - #BOSTechWeek
Hosted by
*⏖*
-‿-EVENT SUMMARY
Most biotech founders don't realize Australia has a faster regulatory path, R&D tax incentives, and world-class trial infrastructure — all while generating FDA-accepted data. This intimate Lunch & Learn brings experienced advisors into the room to break down exactly how (and when) to structure early-stage clinical trials down under. Application-based, limited seats, lunch served.
FULL DESCRIPTION
You've got a promising therapeutic (or device) but you're burning runway waiting on an IND filing. Meanwhile, founders who know the playbook are running Phase I/II trials in Australia — faster enrollment, streamlined regulatory approvals, and an R&D tax incentive that effectively returns up to 43.5 cents on every dollar spent subject to meeting qualifying criteria.
This isn't a surface-level overview. It's a working session built for biotech founders and senior operators who are actively planning (or considering) early-stage clinical trials and want to understand a path most U.S. companies overlook.
Experienced advisors who've structured Australian trials for U.S.-based biotechs will walk through the real mechanics:
- when Australia actually makes sense versus when it doesn't;
- how to navigate the TGA regulatory framework;
- how to structure entities and budgets; and
- the operational realities no slide deck covers.
The format is intentionally intimate to allow for an application based candid conversation. Just the tactical knowledge that gives early-stage companies a genuine edge in getting to clinic faster and more capital-efficiently.
About Acclime: Acclime is a global corporate services and advisory firm supporting international life sciences companies with market entry, clinical trial structuring, R&D advisory, tax, accounting, and ongoing operational support. Acclime works extensively with biotech companies conducting R&D and clinical activity in Australia and across Asia‑Pacific.
About Nucleus Network: Nucleus Network is a global leader in early‑phase clinical trials, supporting first‑in‑human and early development programs across Australia, the U.S., and the UK.
About BioCina: BioCina is a global end‑to‑end CDMO supporting biopharma companies with process development and cGMP clinical and commercial manufacturing across microbial, plasmid DNA, mRNA, and sterile drug products in Australia and globally.
Venue Partner - Ketryx: Ketryx is a Boston‑based software company providing a validated, cloud‑native platform that helps life sciences teams manage quality, regulatory, and clinical development workflows in compliant, scalable ways.
This event is a part of #BOSTechWeek—a week of events hosted by VCs and startups to bring together the tech ecosystem. Learn more at www.tech-week.com.
Guest List
^⎵^
˘◡˘
°ᴗ°